Commonly used human adenovirus (HAdV)-5-based vectors are restricted by their tropism and pre-existing immunity. Here, we characterized novel HAdV-5 vectors pseudotyped with hypervariable regions (HVRs) and surface domains (SDs) of other HAdV types. Hexon-modified HAdV-5 vectors (HV-HVR5, HV-HVR12, HV-SD12 and HV-SD4) could be reconstituted and amplified in human embryonic kidney cells. After infection of various cell lines, we measured transgene expression levels by performing luciferase reporter assays or coagulation factor IX (FIX) ELISA. Dose-dependent studies revealed that luciferase expression levels were comparable for HV-HVR5, HV-SD12 and HV-SD4, whereas HV-HVR12 expression levels were significantly lower. Vector genome copy numbers (VCNs) from genomic DNA and nuclear extracts were then determined by quantitative real-time PCR. Surprisingly, determination of cell-and nuclear fraction-associated VCNs revealed increased VCNs for HV-HVR12 compared with HV-SD12 and HV-HVR5. Increased nuclear fraction-associated HV-HVR12 DNA molecules and decreased transgene expression levels were independent of the cell line used, and we observed the same effect for a hexon-modified high-capacity adenoviral vector encoding canine FIX. In conclusion, studying hexon-modified adenoviruses in vitro demonstrated that HVRs but also flanking hexon regions influence uptake and transgene expression of adenoviral vectors.
INTRODUCTION
Adenoviral-based vectors are essential tools for gene therapy and vaccination purposes. However, their use in broad applications is inhibited because of the restricted liver tropism of the predominantly used human adenovirus (HAdV)-5 in mice and existing anti-adenoviral neutralizing anti-bodies due to their high prevalence in the human population.
The HAdV capsid consists of 240 hexon trimers, 18 penton monomers and 12 fibre trimers, making an icosahedral lattice (Reddy et al., 2010) . In addition to the fibre and penton proteins, the hexon protein plays a major role in virus tropism and neutralization. Although anti-fibre and anti-penton antibodies display a synergistic effect on virus neutralization (Gahéry-Ségard et al., 1998) , hexon is primarily targeted for neutralization in mice and humans (Sumida et al., 2005) . It is estimated that most of the adenoviral neutralizing antibodies are generated against hexon, and *10-15 % against fibre and penton (Roberts et al., 2006) . Importantly, it was shown that neutralization can be partly circumvented when HAdV-5 is pseudotyped with hexon derived from a serotype of the same or a different species (Gall et al., 1998; Roberts et al., 2006; Roy et al., 1998; Youil et al., 2002) . In a pivotal study, it was demonstrated that the exchange of hypervariable regions (HVRs) with sequences of low-seroprevalent serotype 48 (HAdV-48) within hexon of HAdV-5 was able to circumvent preexisting immunity in mice (Roberts et al., 2006) . Hexon also plays a major role in the tropism and inflammatory profile of adenoviral vectors. It is known that coagulation factor X binds to HAdV-5 hexon, resulting in liver tropism (Waddington et al., 2008) . Additionally, coagulation factor X binding to HAdV-5 triggers the innate immune system as well as leading to antiviral inflammatory response against HAdV-5 (Doronin et al., 2012) . trimerization or inter-hexon interaction (Crawford-Miksza & Schnurr, 1996; Ebner et al., 2005; Reddy et al., 2010) . Despite the complexity of the pseudotyped adenovirus hexon, many groups have successfully generated adenovirus hexon chimeras equipped with novel gene therapeutic characteristics (Alba et al., 2009; Khare et al., 2011; Roberts et al., 2006) . It is of note that one study was able to optimize vector production by identifying a suppressor mutation in hexon (Bruder et al., 2013) . Different strategies were used to genetically modify hexon for HAdV-5-based vectors. Youil et al. (2002) exchanged the complete HAdV-5 hexon gene with hexon sequences from different species and found that only hexon exchanges derived from the same species could be rescued successfully. Furthermore, HAdV-5 vector containing HVRs from HAdV-48 showed reduced liver tropism associated with increased inflammatory responses . Another study demonstrated that pseudotyping specifically HVR5 or 7 of HAdV-5 with HAdV-26 abolished the binding of coagulation factor X with HAd5 hexon (Alba et al., 2009) . Various other investigations also revealed that genetic modification of HVRs strongly influenced biodistribution (e.g. efficient liver detargeting) after systemic administration in vivo by interfering with the coagulation factor X binding properties of the adenovirus surface and by affecting inflammatory responses Khare et al., 2011; Ma et al., 2015) .
Therefore, genetic hexon modification is highly desirable as it may create vectors with novel tropism along with circumventing pre-existing immunity. In our previous study we generated hexon-modified helper viruses pseudotyped with HVRs and, for the first time, the hexon surface domain (SD) (Fig. 1a) derived from rare serotypes (Mü ck-Häusl et al., 2015) . Here, we characterized and explored the in vitro properties of these novel hexon-modified viruses HV-HVR12, HV-SD12 and HV-SD4. Either the SD or the HVR was precisely exchanged in the HAdV-5 hexon. Previous approaches also exchanged the HVR and in other studies the complete hexon sequence was exchanged. The figure is modified from Roberts et al. (2006) . (b) Viruses (HV-HVR5, HV-HVR12, HV-SD12 and HV-SD4) were produced in HEK293 cells and purified using caesium chloride gradients. Final vector preparations showed comparable physical titres. NS, Not significant (P.0.05). (c) Chimeraspecific PCRs were designed to check the integrity of chimeric viruses. Mean¡SD is shown including all viral largescale preparations (n53 for HV-HVR5 and HV-HVR12; n52 for HV-SD12 and HV-SD4). NS, Not significant (P.0.05).
RESULTS

Large-scale amplification and characterization of hexon chimeric adenoviruses
Pre-existing immunity and the distinct tropism of adenoviruses limit the broad use of recombinant adenovirus in gene therapy or vaccination approaches. Both features can be addressed by altering immunogenic epitopes in the adenovirus capsid, specifically located in hexon (Roberts et al., 2006) . In our recent study we pseudotyped HAdV-12 and HAdV-4 HVRs and SDs in HAdV-5-based first-generation adenoviral vectors deleted for the early viral genes E1 and E3. We successfully generated novel hexon-modified viruses HV-HVR12, HV-SD12 and HV-SD4 encoding luciferase (Mück-Häusl et al., 2015) . Our strategy of introducing hexon modifications into hexon and a comparison with former approaches is schematically outlined in Fig. 1(a) . These hexon-modified adenoviruses were amplified in HEK293 cells in a largescale manner followed by purification using caesium chloride gradient purification as described previously (Jager et al., 2009) . Viral particles obtained after three independent large-scale preparations of each virus revealed comparable physical titres for all four chimeras (Fig. 1b) . Stability of the replaced chimeric sequence after large-scale amplification was checked by hexon chimera-specific PCR (Fig. 1c) .
Next, dose-dependent infection studies were performed in HEK293 and A549 cells. Confluent monolayers of A549 cells were infected with chimeric adenoviruses at various virus particle numbers (vps) per cell (vps per cell) followed by measurement of luciferase expression levels. We found that there was a dose-dependent increase in luciferase expression for HV-HVR5, HV-SD12 and HV-SD4. In contrast, HV-HVR12 luciferase expression levels remained 100-fold lower than other chimeric viruses, especially at higher doses (Fig. 2a) . To rule out if this was a cell-type specific phenomenon, we repeated the dose-dependent studies in HEK293 cells and observed a similar effect on vector-derived expression levels (Fig. 2b) .
Infection with HV-HVR12 results in decreased transgene expression levels associated with increased vector genome copy numbers (VCNs)
To further characterize vectors in vitro, we checked luciferase expression levels and measured VCNs after infection of human and mouse liver cells. Huh7 (human liver carcinoma-derived cells) and MMHD3 (immortalized hepatocytes from mouse) were checked for transgene expression levels and VCNs after infection with hexon-modified viruses. Confluent monolayers were incubated with 10, 100 and 1000 vps per cell of chimeras followed by luciferase detection and VCN quantification 48 h post-transduction. We found that HV-HVR12-derived luciferase expression levels in Huh7 and MMHD3 cells were increased compared with HV-HVR5 expression at a viral dose of 10 vps per cell (Fig. 3a, b) . However, at a viral doses of 100 and 1000 vps per cell, infection with HV-HVR12 resulted in significantly decreased transgene expression levels compared with HV-HVR5 (Fig. 3a, b) . In contrast, for HV-SD4 and HV-SD12 the transgene expression levels directly correlated with an increasing viral dose (Fig. 3a) . These data were in concordance with dose-dependent studies performed in A549 and HEK293 cells (Fig. 2a, b) .
VCN quantification revealed that HV-HVR12 had either similar (1000 vps per cell) or higher VCNs (10 and 100 vps per cell) than HV-HVR5 (Fig. 3c, d ) in both cell lines. As all in vitro observations for HV-HVR12 were associated with high VCNs and comparably low transgene expression levels, we speculated that nuclear import of adenoviral genomes may be influenced by the chimeric capsid. Thus, we incubated monolayers of A549 cells with three different viral doses per cell. At 5 h post-infection, nuclei were isolated followed by nuclei DNA isolation and VCN were quantified. We found that nuclear fraction-related HV-HVR12 genomes were up to 10-fold more compared with HV-HVR5, HV-SD12 and HV-SD4 (Fig. 4 ).
Generation and in vitro characterization of a canine coagulation factor IX (cFIX) encoding high-capacity adenoviral (HCAdV) vector using HV-HVR12
To address the question whether this phenomenon is independent of DNA sequences contained in the capsid, we analysed HCAdV vectors packaged into a hexon chimeric capsid. All hexon-modified first-generation adenoviruses generated in this study can also be used as helper viruses for the production of HCAdV lacking all viral coding sequences, because they contained a packaging signal flanked by the Cre recombinase recognition sites lox P. In Cre recombinase-expressing producer cells the packaging signal is excised, enabling the HCAdV with an intact packaging signal to be packaged efficiently. Thus, we used HV-HVR12 to package a HCAdV genome encoding cFIX under the control of the liver-specific a1-antitrypsin promoter (HCA-HVR12-cFIX) (Fig. 5a) . Moreover, as a control we packaged the identical genome in regular HAdV-5 capsids (HCA-HVR5-cFIX). Both HCAdV vectors were produced using an established protocol (Jager et al., 2009 ) based on a large-scale spinner culture system followed by purification using caesium chloride gradients and subsequent titration (Fig. 5b) . Next, confluent monolayers of Huh7 cells were infected with HCA-HVR5-cFIX and HCA-HVR12-cFIX followed by cFIX quantification in the cell supernatant by ELISA (Fig. 5c ) and quantification of VCNs by quantitative real-time PCR (qRT-PCR) (Fig. 5d) . We found that gene-deleted HCA-HVR12-cFIX mimicked the in vitro behaviour of HV-HVR12, as low transgene expression combined with high copy numbers of cFIX were measured. Notably, HCA-HVR12-cFIX showed nearly 1000-fold difference in cFIX copies at 10 vps per cell.
Neutralization of hexon chimeric vectors with anti-HAdV-5 serum
To measure to what extent novel hexon chimeric viruses are neutralized by anti-HAdV-5 sera, antibody assays were performed according to a previously published approach (Sprangers et al., 2003) . Reciprocal dilution of canine serum (Hausl et al., 2010) et al., 2006) displayed the most efficient serum escape, whereas HV-SD12 was similar to HV-HVR5 (Fig. 6 ). Note that neutralization assays were not possible for HV-HVR12, because total luciferase levels remained unchanged even after serum incubation, rendering comparison with HV-HVR5 incalculable.
DISCUSSION
Adenovirus-based gene therapeutic approaches are restricted by pre-existing immune responses and a limited tropism of commonly used adenoviral vectors. Both factors are strongly influenced by the adenovirus hexon. In a previous study we generated three novel hexon-modified vectors and in this study we characterized these hexon chimeric adenoviruses (Mück-Häusl et al., 2015) . We either precisely exchanged the HVRs or, as a novel option, we exchanged the SD domain of hexon (Fig. 1a) .
When performing large-scale amplification, all chimeric adenoviruses were produced at high physical titres, indicating that virus amplification was not influenced by the hexon modification.
In vitro transduction of various cell lines (A549, HEK293, human and mouse hepatocytes) by HV-HVR5, HV-SD12 and HV-SD4 resulted in dose-dependent increases in luciferase expression. However, HV-HVR12 luciferase expression remained 10-100 times lower compared with other vectors (Fig. 2) , and we observed an inverse correlation between VCNs and luciferase expression levels for HV-HVR12. In contrast to other vectors tested, HV-HVR12 revealed 10-100 times increased VCNs at low viral dose and at the same time significantly lower luciferase expression levels (Fig. 3) . Taken together, these results indicate that high transduction efficiencies of HV-HVR12 can be associated with a negative effect on transgene expression. *Significant difference between the two groups (P,0.05).
Hexon surface domain exchanges of HAdV-5
Although we can only speculate about the reasons that may be responsible for this observation, recent studies showed that adenoviral hexon plays a critical role in nuclear import of the viral genome by interacting with nuclear pore complex and histone H1 (Cassany et al., 2015; Trotman et al., 2001 ). In addition, we repeatedly found that in fractions of total DNA isolated from infected cells, numbers of HV-HVR12 genomes were significantly higher at lower doses (10 vps per cell) compared with HV-HVR5 (Figs 3 and 5) , indicating a dose-dependent effect. Potentially, uptake of viral genomes and subsequent transcription levels derived from the viral genome may somehow be negatively influenced by the amount of hexon in the infected cell. Although macroscopically no obvious signs of stronger cellular toxicity were observed for the group which received HV-HVR12, it needs to be addressed whether cellular toxicity may be responsible for the decrease in HV-HVR12 transgene expression when using an increased viral load. This may also raise the question whether the chimeric hexon itself causes cellular toxicity or whether hexondependent innate immune responses are involved.
We found that nuclear fraction-related vector genomes were increased for HV-HVR12 compared with HV-SD12 and HV-HVR5 (Fig. 4) . Several reasons may be considered as explaining this finding. For instance, the introduced hexon modification could either change the overall capsid stability, thereby increasing cytosolic degradation, or decreased capsid stability could enhance cytosolic viral DNA detection leading to increased IFN response and decreased transgene expression. However, further experiments need to be performed to study capsid stability of HV-HVR12 and nuclear import of viral genomes of hexon-modified and -unmodified viruses.
To further support our results, we performed similar experiments based on hexon-modified HCAdVs lacking all adenoviral coding sequences (Fig. 5) . Interestingly we observed the same phenomenon for HCAdV encoding cFIX (HCA-HVR12-cFIX). In comparison with HCA-HVR5-cFIX (unmodified capsid), transgene expression was lower but at the same time VCNs were higher for HCA-HVR12-cFIX. As both HCAdVs are deleted for all viral coding sequences, one could speculate that leaky expression of adenoviral proteins from the incoming viral vector genome may not be involved, but rather the incoming modified hexon protein itself. However, further experiments need to be performed to determine the mechanism responsible for this observation.
Neutralization assays performed in this study revealed that HV-SD4 and the previously published vector HV-HVR48 carrying HVRs from HAdV-48 can escape neutralizing antibodies directed against HAdV-5 (Fig. 6) . Moreover, escape from neutralizing antibodies for HV-SD12 was similar to HV-HVR5, indicating effective binding of HAdV-5-specific antibodies. Unfortunately it was not possible to perform neutralization assays for HV-HVR12 due to the lack of sufficient luciferase expression levels.
In summary, we characterized novel hexon chimeric adenoviruses which show distinct in vitro properties. We demonstrate that SD exchange may represent a valuable alternative to generate novel hexon chimeric vectors. Interestingly, HV-HVR12 and HV-SD12 show opposite effects on transduction and transgene expression, hinting towards sequences outside of the HVR influencing uptake and transgene expression. However, further studies need to be performed and additional genetically modified chimeric adenoviruses need to be produced to narrow down which part of the hexon protein outside of the HVR may be responsible for this phenomenon. Undoubtedly, hexon pseudotyping remains unpredictable; however, if successful, a novel adenoviral vector with distinct features can be created. Future studies should investigate the in vivo properties of these hexon chimeric adenoviruses addressing biodistribution and immune responses directed against the incoming viral vector.
METHODS
Cell culture. A549, Huh7 and HEK293 cells were grown in DMEM (PAN Biotech) medium supplemented with 10 % FBS (PAN Biotech) and 1| Penstrep (PAN Biotech). Additionally, Huh7 cells were also supplemented with 1| MEM Non-essential amino acid (PAN Biotech). MMHD3 cells were grown in RPMI 1640 with 10 % FCS, epidermal growth factor (55 ng ml 21 ), insulin-like growth factor II (16 ng ml 21 ), insulin (10 mg ml 21 ) and antibiotics as described previously (Amicone et al., 1997) .
Production of hexon-modified chimeric viruses. All hexonmodified adenoviruses (HV-HVR12, HV-SD12, HV-SD4 and HV-HVR48) were cloned, reconstructed and produced as described previously (Jager et al., 2009; Mück-Häusl et al., 2015) . Briefly, helper viruses were infected in monolayers of HEK293 for 48 h and collected. Collected lysates were freeze/thawed followed by purification with caesium chloride gradient ultracentrifugation. Chimeric adenoviruses were collected from the caesium chloride gradient and subjected to buffer exchange using PD-10 columns (Amersham Biotech). Different aliquots of virus were produced and stored at 280 uC.
Titration of hexon-modified viruses. All helper viruses were titrated as described previously using optical titration measurement (Jager et al., 2009) . Briefly, 25 ml virus mixed with 475 ml lysis buffer [10 mM Tris/HCl (pH 7.5), 10 mM EDTA (pH 8.0), 0.5 % SDS] was incubated for 20 min at 25 uC followed by centrifugation at 16 200 g for 2 min. Subsequently, A 260 was measured. The following formula was used to calculate final physical viral titres: viral particle units5(A 260 )|(dilution factor)|(1.1|10 12 )|(36)/(size of adenovirus genome in kb), expressed as vps ml -1 . In this study this number was divided by 1000 to calculate vps ml 21 .
In vitro firefly luciferase assay. Luciferase quantification was done using a Steady-Glo Luciferase detection kit (Promega). Huh7 and MMHD3 cells were seeded on 24-well plates. Prior to infection and for normalization the cells were seeded using a master mix distribution that ensured similar confluence at the time of infection. Confluent monolayers were incubated with the respective helper virus at 10, 100 and 1000 vps per cell for 48 h. Afterwards medium was removed and Steady-Glo reagent (Promega) was added to the monolayers. Cells were incubated at 37 uC for 10-15 min and transferred to flat-bottom 96-well format dishes compatible with a Genios (Tecan) luminometer.
HEK293 and A549 cells used for dose-dependent luciferase activity were seeded on 96-well flat-bottom luminometer-compatible plates (Greiner Bio-One). Respective helper viruses were incubated for 24 h followed by luciferase detection.
VCN quantification. Monolayers of the various cell lines used were incubated with the respective helper virus at 10, 100 and 1000 vps per cell for 24 h. Genomic DNA isolation was then performed using a Promega Wizard Genomic DNA Purification kit. DNA samples obtained were subjected to quantification of the L3 region of the helper virus using ssoAdvanced Universal probe mix (Bio-Rad). Primers used for L3 detection were L3 detection forward (59-GAG-TTGGCACCCCTATTCGA-39), L3 detection reverse (59-ATGCCA CATCCGTTGACTTG-39) and the L3 detection probe (59-FAM-CCACCCGTGTGTACCTGGTGGACA-TAMRA-39). Human b 2 -microglobulin (B2M) quantification was conducted for quantification of cell numbers using the primers hB2M forward (59-TGCTGTCT-CCATGTTTGATGTATCT-39) and hB2M reverse (59-TCTCTGCT-CCCCACCTCTAAGT-39). Note that human B2M qRT-PCR was performed using a Luminaris Colour HiGreen qPCR Master Mix.
qRT-PCR to detect the cFIX gene in the vectors HCA-HVR5-cFIX and HCA-HVR12-cFIX was described previously using the primers cFIX forward (59-CTGACCTGGGACAGTGAATGAT-39) and cFIX reverse (59-GCCTGGTGATTCTGCCATGAT-39) (Zhang et al., 2013) . Sequences of all primers used for qRT-PCRs were also described in our previous study (Zhang et al., 2013) . VCNs were normalized by performing qRT-PCR detecting the human B2M gene as internal control to determine the number of total genomes in analysed samples. Human B2M is a housekeeping gene present in every human cell in duplicate and thus the number of cells can be determined in the given sample. Final normalized VCNs displayed in the figures are therefore based on the same amount of genomic DNA and total number of cells.
Neutralizing antibody assay. Neutralizing antibody assays were performed as described previously (Sprangers et al., 2003) . Serum was used from a pre-immunized dog injected with a HCAdV-5-based vector (Hausl et al., 2010) . Briefly, serial dilutions of serum was made and mixed with 0.5 ml hexon-modified virus in a 96-well luminometer-compatible plate. This mixture was incubated at 37 uC for 15 min. HEK293 cells (n510 000) with growth medium after treatment with trypsin were added to the serum/virus mixture. After 24 h, medium was removed and Steady-Glo luciferase reagent was added. After 15 min of incubation the plate was directly transferred into the luminometer (Genios Tecan).
Production of HCAdV vectors HCA-HVR5-cFIX and HCA-HVR12-cFIX. The vector HCA-HVR5-cFIX (referred to as HC-AdVTcFIX in our previous study) encoding cFIX under the control of a liver-specific promoter was described in our previous publication (Hausl et al., 2010) . Hexon-modified HCAdVs were produced according to a protocol described previously (Jager et al., 2009) . Briefly, 116 cells were transfected with the linearized HCAdV genome.
Helper viruses HV-HVR5 and HV-HVR12 containing HVR from HAdV-5 and HAdV-12 (Mück-Häusl et al., 2015) were used for serial amplification that resulted in the hexon-modified HCAdV packaged into the hexon chimeric capsid derived from HV-HVR12 (HCA-HVR12-cFIX) and the unmodified capsid derived from HAdV-5 (HCA-HVR5-cFIX). Large-scale production in a spinner culture system of HCAdV-HVR12-cFIX and titration were performed as described previously (Jager et al., 2009) . In brief, either the physical viral titre based on measuring the A 260 was determined (vps ml 21 ) as described for hexon-modified viruses or transducing units (TU) of the high-capacity vectors were determined. In the latter case, HEK293 cells were infected with the respective HCAdV vectors and after 3 h the total viral vector genomes were measured in isolated total DNA of infected cells.
cFIX ELISA. Measurement of cFIX levels was performed by ELISA as described previously (Hausl et al., 2010) . Briefly, ELISA plates (Greiner Bio-One) were coated with polyclonal rabbit anti-FIX primary antibody (RACIX-IG; Affinity Biologicals) after diluting 1 : 250. After incubation with samples, sheep HRP-conjugated secondary antibody (SACIX-HRP; Affinity Biologicals) diluted 1 : 1000 was added followed by adding the substrate (SIGMAFAST OPD tablet; Sigma-Aldrich). A standard curve was produced by serial dilution of normal canine serum with a concentration range of 5-250 ng ml 21 .
Nuclei isolation. Isolation of nuclei was performed as described previously (Gallaher & Berk, 2013) . Briefly, A549 cells were infected with various helper viruses for 5 h followed by treatment with NP-40 lysis buffer. Isolation of DNA from nuclei was performed as described previously (Jager et al., 2009) . Luminaris Colour HiGreen qPCR master mix (Thermo Scientific) was used for quantification of the viral L3 hexon region using the primers listed above. qRT-PCR data were normalized to total cells using B2M as internal control.
Statistical analysis. All data are reported as mean+SD unless otherwise noted. Statistical comparison was made using the two-tailed Student's test and a value of Pv0.05 was considered to be significant compared with the respective control group.
